CN114901289A - 用于治疗alk阴性癌症和浆细胞介导的疾病的alk抑制剂 - Google Patents

用于治疗alk阴性癌症和浆细胞介导的疾病的alk抑制剂 Download PDF

Info

Publication number
CN114901289A
CN114901289A CN202080089754.2A CN202080089754A CN114901289A CN 114901289 A CN114901289 A CN 114901289A CN 202080089754 A CN202080089754 A CN 202080089754A CN 114901289 A CN114901289 A CN 114901289A
Authority
CN
China
Prior art keywords
alk
cancer
ltk
cells
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080089754.2A
Other languages
English (en)
Chinese (zh)
Inventor
H·法尔罕
L·蒙特
K·塔斯肯
S·斯坎兰德
M·吉利伯托
F·赫勒姆·施杰斯沃德
C·德里森
L·贝西
A·贝西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitetet i Oslo
Original Assignee
Universitetet i Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet i Oslo filed Critical Universitetet i Oslo
Publication of CN114901289A publication Critical patent/CN114901289A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202080089754.2A 2019-10-28 2020-03-12 用于治疗alk阴性癌症和浆细胞介导的疾病的alk抑制剂 Pending CN114901289A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201915618A GB201915618D0 (en) 2019-10-28 2019-10-28 ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
GB1915618.1 2019-10-28
PCT/EP2020/056698 WO2021083555A1 (en) 2019-10-28 2020-03-12 Alk inhibitors for treatment of alk-negative cancer and plasma cell-mediated diseases

Publications (1)

Publication Number Publication Date
CN114901289A true CN114901289A (zh) 2022-08-12

Family

ID=68768829

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080089754.2A Pending CN114901289A (zh) 2019-10-28 2020-03-12 用于治疗alk阴性癌症和浆细胞介导的疾病的alk抑制剂

Country Status (9)

Country Link
US (1) US12465607B2 (https=)
EP (1) EP4051288A1 (https=)
JP (1) JP7629228B2 (https=)
KR (1) KR102946955B1 (https=)
CN (1) CN114901289A (https=)
AU (1) AU2020374150B2 (https=)
CA (1) CA3159339A1 (https=)
GB (1) GB201915618D0 (https=)
WO (1) WO2021083555A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024193693A1 (zh) * 2023-03-22 2024-09-26 苏州亚盛药业有限公司 药物组合及其应用
CN119700981A (zh) * 2024-12-24 2025-03-28 中南大学湘雅二医院 Alk/ltk抑制剂在制备治疗和/或预防慢性淋巴细胞白血病的产品中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230091284A (ko) * 2021-12-16 2023-06-23 부산대학교 산학협력단 Surf4 억제제를 포함하는 혈액암의 예방 또는 치료용 약학적 조성물
WO2024017334A1 (zh) * 2022-07-22 2024-01-25 贝达药业股份有限公司 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
CN115993453B (zh) * 2022-07-22 2025-03-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024059525A2 (en) * 2022-09-12 2024-03-21 Endotarget, Inc. Compounds and methods for the targeted degradation of anaplastic lymphoma kinase and ros1 kinase

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150290204A1 (en) * 2012-11-07 2015-10-15 Novartis Ag Combination therapy
CN105294649A (zh) * 2014-07-30 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
US20170173020A1 (en) * 2014-03-28 2017-06-22 Universitá Degli Studi Di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
US20170274074A1 (en) * 2014-08-25 2017-09-28 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US20170281624A1 (en) * 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
US20180282415A1 (en) * 2015-09-30 2018-10-04 Merck Patent Gmbh Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009233963B2 (en) 2008-04-07 2011-10-06 Irm Llc Compounds and compositions as kinase inhibitors
US8904383B2 (en) 2008-04-10 2014-12-02 Hewlett-Packard Development Company, L.P. Virtual machine migration according to environmental data
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
BR112013015000A2 (pt) 2010-12-17 2016-08-09 Novartis Ag formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
JPWO2019039390A1 (ja) 2017-08-25 2020-07-30 国立大学法人東海国立大学機構 若年性骨髄単球性白血病治療薬
WO2019113345A1 (en) 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
CN110063956A (zh) * 2018-01-20 2019-07-30 中国科学院上海药物研究所 治疗肝癌的药物组合和方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150290204A1 (en) * 2012-11-07 2015-10-15 Novartis Ag Combination therapy
US20170173020A1 (en) * 2014-03-28 2017-06-22 Universitá Degli Studi Di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
CN105294649A (zh) * 2014-07-30 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
US20170274074A1 (en) * 2014-08-25 2017-09-28 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US20170281624A1 (en) * 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
US20180282415A1 (en) * 2015-09-30 2018-10-04 Merck Patent Gmbh Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAEBONG JANG, ET AL.: ""Discovery of a potent dual ALK and EGFR T790M inhibitor"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 136, pages 497 - 510, XP055766277, DOI: 10.1016/j.ejmech.2017.04.079 *
JINGCHUN SUN, ET AL.: ""A systematic analysis of FDA-approved anticancer drugs"", 《BMC SYSTEMS BIOLOGY》, vol. 11, pages 87 *
杜萍等: ""EML4-ALK 融合基因阳性分子靶向药物研究进展"", 《中国新药杂志》, vol. 24, no. 16, pages 1856 - 1861 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024193693A1 (zh) * 2023-03-22 2024-09-26 苏州亚盛药业有限公司 药物组合及其应用
CN119700981A (zh) * 2024-12-24 2025-03-28 中南大学湘雅二医院 Alk/ltk抑制剂在制备治疗和/或预防慢性淋巴细胞白血病的产品中的应用

Also Published As

Publication number Publication date
KR102946955B1 (ko) 2026-04-02
CA3159339A1 (en) 2021-05-06
JP2022554258A (ja) 2022-12-28
GB201915618D0 (en) 2019-12-11
WO2021083555A1 (en) 2021-05-06
EP4051288A1 (en) 2022-09-07
US20220401444A1 (en) 2022-12-22
AU2020374150B2 (en) 2025-12-18
JP7629228B2 (ja) 2025-02-13
US12465607B2 (en) 2025-11-11
KR20220098158A (ko) 2022-07-11
AU2020374150A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
KR102946955B1 (ko) Alk-음성 암 및 형질 세포-매개 질환의 치료를 위한 alk 억제제
Knudsen et al. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
Hurtz et al. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
Agarwal et al. G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation
Takezawa et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation
US10017767B2 (en) Targets in multiple myeloma and other disorders
Na et al. Endogenous prostaglandin E2 potentiates anti‐inflammatory phenotype of macrophage through the CREB‐C/EBP‐β cascade
JP2023546217A (ja) がん、自己免疫障害、及び炎症性障害の処置におけるｎ－ミリストイルトランスフェラーゼ（ｎｍｔ）阻害剤の使用
JP2012187105A (ja) ＧＳＫ３β阻害効果に基づく抗がん剤の評価方法
Gnocchi et al. Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma
Rampal et al. Therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms
Bahn et al. TGF-β antagonism synergizes with PPARγ agonism to reduce fibrosis and enhance beige adipogenesis
JP2007526882A (ja) リンパ球性白血病を治療するためのロスコビチンの使用
TW202112368A (zh) 用於治療有關dux4表現之疾病的抑制劑組合
KR20150131155A (ko) 종양 약역학적 반응의 바이오마커
Liu et al. [Retracted] lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia
US20210252009A1 (en) Composition comprising flt3 inhibitor as effective ingredient for inhibiting drug resistance in chronic myelogenous leukemia
WO2015134603A2 (en) Methods for treating cancer
US20230210849A1 (en) Cadherin-11 inhibitor formulation and its uses in immunotherapy
US20170027955A1 (en) Expression levels of bcl-xl, bcl2, bcl-w, and bad and cancer therapies
JP7759032B2 (ja) 脳血管攣縮抑制剤
US20100105745A1 (en) Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
Dmello Discovering new treatments for colorectal cancer
Wodi Targeting the Splice Factor Kinases SRPK1 and CLK1 in Leukaemia
Agarwal et al. G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220812

WD01 Invention patent application deemed withdrawn after publication